News
Preclinical news: destroying brain cancer!
In preclinical results, our lead cancer drug, TLD-1433, has been shown to destroy the human brain cancer glioblastoma multiforme (GBM) when activated by x-rays.
In preclinical results, our lead cancer drug, TLD-1433, has been shown to destroy the human brain cancer glioblastoma multiforme (GBM) when activated by x-rays.
